Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk.

Publication ,  Journal Article
Blitz, JD; Haile, M; Kline, R; Franco, L; Didehvar, S; Pachter, HL; Newman, E; Bekker, A
Published in: Am J Ther
September 2012

Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) are common occurrences (50%-80%) after laparoscopic surgery. Palonosetron (Pal), the newest 5-HT3 antagonist, is an effective antiemetic that has advantages in treating PDNV due to its prolonged duration of action. We hypothesized that a combination of Pal and dexamethazone (Dex) could further improve the efficacy of the treatment in comparison to Pal alone in patients at high risk for PONV. Patients scheduled to undergo laparoscopic surgeries under general anesthesia were randomized to receive 8-mg dexamethasone + 0.075-mg palonosetron (Pal + Dex) or an equivalent volume of saline + 0.075 mg palonosetron (Pal). Data was collected at defined postoperative times (2, 6, 12, 24, and 72 hours). All patients also completed an 18-question QOL-Functional Living Index-Emesis instrument at 96 hours. We enrolled 118 patients, ASA 1-2, with at least 3 PONV risk factors, who were undergoing outpatient surgery. Both groups had a low incidence of vomiting in the PACU (Pal + Dex, 1.7%; Pal, 6.8%) and at 72 hours (0.0% both groups). Complete response (no vomiting, no rescue medication) was not different between treatment groups for any time intervals. Cumulative success rates over the entire 72 hours were 60.4% (Pal + Dex) versus 60.0% (Pal). The Pal + Dex group showed a trend toward greater satisfaction on the QOL- Functional Living Index-Emesis scores with the greatest differences in the "nausea domain". The combination therapy of palonosetron + dexamethasone did not reduce the incidence of PONV or PDNV when compared with palonosetron alone. There was no change in comparative efficacy over 72 hours, most likely due to the low incidence of PDNV in both groups.

Duke Scholars

Published In

Am J Ther

DOI

EISSN

1536-3686

Publication Date

September 2012

Volume

19

Issue

5

Start / End Page

324 / 329

Location

United States

Related Subject Headings

  • Time Factors
  • Risk Factors
  • Quinuclidines
  • Quality of Life
  • Prospective Studies
  • Postoperative Nausea and Vomiting
  • Palonosetron
  • Male
  • Laparoscopy
  • Isoquinolines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Blitz, J. D., Haile, M., Kline, R., Franco, L., Didehvar, S., Pachter, H. L., … Bekker, A. (2012). A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk. Am J Ther, 19(5), 324–329. https://doi.org/10.1097/MJT.0b013e318209dff1
Blitz, Jeanna D., Michael Haile, Richard Kline, Lola Franco, Sorosch Didehvar, H Leon Pachter, Elliot Newman, and Alex Bekker. “A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk.Am J Ther 19, no. 5 (September 2012): 324–29. https://doi.org/10.1097/MJT.0b013e318209dff1.

Published In

Am J Ther

DOI

EISSN

1536-3686

Publication Date

September 2012

Volume

19

Issue

5

Start / End Page

324 / 329

Location

United States

Related Subject Headings

  • Time Factors
  • Risk Factors
  • Quinuclidines
  • Quality of Life
  • Prospective Studies
  • Postoperative Nausea and Vomiting
  • Palonosetron
  • Male
  • Laparoscopy
  • Isoquinolines